Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia. (JEWEL II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00174304|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 8, 2010
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Hyperlipidemia||Drug: Amlodipine/atorvastatin single pill||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1120 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)|
|Study Start Date :||October 2004|
|Study Completion Date :||September 2006|
- To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing percentage of subjects who reach target BP and LDL-C targets as defined by their governing guidelines.
- To asses changes since baseline of lab parameters, BP, safety of titration of amlodipine.atorvastatin to reach targets, to validate Expectations and Satisfaction with Treatment questionnaires.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00174304
Show 101 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|